We previously reported that allogeneic, intraperitoneally administered "Neo-Islets," composed 23 of cultured pancreatic islet cells co-aggregated with high numbers of immunoprotective and 24 cytoprotective Adipose-derived Stem Cells, reestablished, through omental engraftment, 25 redifferentiation and splenic and omental up-regulation of Regulatory T-cells, normoglycemia in 26 autoimmune Type-1 Diabetic Non-Obese Diabetic (NOD) mice without the use of 27 immunosuppressive agents or encapsulation devices. Based on these observations, we are 28 currently testing this Neo-Islet technology in an FDA guided Pilot Study (INAD 012-776) in 29 insulin-dependent, spontaneously diabetic pet dogs by the intraperitoneal administration of 30 2x10e5 Neo-Islets/kilogram body weight to metabolically controlled (blood glucose, 31 triglycerides, thyroid and adrenal functions) animals under sedation and local anesthesia and 32 ultrasound guidance. We report here initial observations on the first 4 Neo-Islet-treated, insulin 33 dependent pet dogs that are now in the intermediate-term follow-up phase of the study (> 6 34 months post treatment). Current results indicate that in dogs, Neo-Islets appear to engraft, 35 redifferentiate and physiologically produce insulin, and are neither rejected by auto-or allo-36 immune attacks, as evidenced by (a) an absent IgG response to the allogeneic cells contained in 37 the administered Neo-Islets, and (b) progressively improved glycemic control that achieves up to 38 a 50% reduction in daily insulin needs paralleled by a significant fall in serum glucose levels. 39 This is accomplished without the use of anti-rejection drugs or encapsulation devices. No 40 adverse or serious adverse events related to the Neo-Islet administration have been observed to 41 date. We conclude that this minimally invasive therapy has significant translational relevance to 42 veterinary and clinical Type 1 Diabetes Mellitus by achieving complete and at this point partial 43 glycemic control in two species, i.e., diabetic mice and dogs, respectively. 48 by lack of insulin secretion in response to glucose, resulting in hyperglycemia, acid-base and 49 electrolyte disorders, polydipsia, polyuria and weight loss, and is accompanied by a broad 50 spectrum of diabetes-induced end organ and other complications, including blindness due to 51 retinopathy and cataracts, opportunistic infections, neurological and other serious micro-and 52 macro-vascular complications [4-6]. Although dogs were the model in which insulin was 53 originally discovered, and remain a major large animal model for the refinement of diabetic 54 treatments such as pancreas and islet cell transplants, almost no advances in the treatment for 55 diabetic dogs have been made in the last 50 years [7]. A few studies have examined xeno-or 56 allogeneic islet transplantation to reverse or ameliorate diabetes in dogs and have had varying 57 degrees of success. Yet, insulin replacement therapy and blood glucose monitoring remain the 58 only currently available therapy for these animals [7-9]. Due to the challenges of medically 59 managing a diabetic dog, up to 40% of owners regrettably opt to euthanize their dogs within a 60 day of diagnosis rather than treat them [1,10]. 61 While the pathogenic mechanisms of canine T1DM are still incompletely understood, there 62 is evidence that autoimmunity plays a role in approximately 1/3 of cases [3,4,7,10-12]. T1DM 63 occurs with equal frequency in male and female neutered dogs, but as with Non-Obese Diabetic 64 (NOD) mice, at higher frequency in intact females vs. males, suggesting a role for female 65 hormones in the development of the disease in dogs [1,3,13-15]. While T1DM affects both 66 juvenile and adult dogs [1,3,7], it is more commonly seen in adults, generally diagnosed between 4 67 the ages of 3 and 15 years [3,10]. Some groups have reported isolation of auto-antibodies to 68
Introduction 45
Diabetes Mellitus is a common endocrine disorder in dogs, and it is estimated that there are 46 currently 700,000 insulin-dependent pet dogs in the US [1] [2] [3] [4] . Their care is burdensome and expensive for their owners. As in humans, Type 1 Diabetes Mellitus (T1DM) in dogs is caused rtPCR was carried out as described in our previous publication [21] using the reagents and 177 primers listed in S1 Table. In brief, RQ was calculated through normalization to internal 178 (deltaCT; beta actin and beta 2 microglobulin) and external controls (delta-deltaCT; parent cells), 
